View in EDS HTML Full Text PDF Full Text

A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer.

Saved in:
Bibliographic Details
Title: A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer.
Authors: Waks AG; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Desai NV; Harvard Medical School, Boston, MA, USA.; Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA., Li T; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA., Poorvu PD; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Partridge AH; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Sinclair N; Harvard Medical School, Boston, MA, USA.; Hematology/Oncology, Dana-Farber/Brigham and Women's Cancer Center at Milford, Milford, MA, USA., Spring LM; Harvard Medical School, Boston, MA, USA.; Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA., Faggen M; Harvard Medical School, Boston, MA, USA.; Hematology/Oncology, Dana-Farber/Brigham and Women's Cancer Center at South Shore Hospital, South Weymouth, MA, USA., Constantine M; Harvard Medical School, Boston, MA, USA.; Hematology/Oncology, Dana-Farber/Brigham and Women's Cancer Center at Milford, Milford, MA, USA., Metzger O; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Alberti J; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Deane J; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Clinical Affairs, TransMedics, Inc, Andover, MA, USA., Rosenberg SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA., Frank E; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA., Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Krop IE; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Yale Cancer Center, New Haven, CT, USA., Tung NM; Harvard Medical School, Boston, MA, USA.; Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA., Tayob N; Harvard Medical School, Boston, MA, USA.; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA., King TA; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA., Mittendorf EA; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA., Winer EP; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Eric.winer@yale.edu.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA. Eric.winer@yale.edu.; Harvard Medical School, Boston, MA, USA. Eric.winer@yale.edu.; Yale Cancer Center, New Haven, CT, USA. Eric.winer@yale.edu.
Source: NPJ breast cancer [NPJ Breast Cancer] 2022 May 10; Vol. 8 (1), pp. 63. Date of Electronic Publication: 2022 May 10.
Publication Type: Journal Article
Journal Info: Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35538105
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Waks+AG%22">Waks AG</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Desai+NV%22">Desai NV</searchLink>; Harvard Medical School, Boston, MA, USA.; Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Li+T%22">Li T</searchLink>; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Poorvu+PD%22">Poorvu PD</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Partridge+AH%22">Partridge AH</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Sinclair+N%22">Sinclair N</searchLink>; Harvard Medical School, Boston, MA, USA.; Hematology/Oncology, Dana-Farber/Brigham and Women's Cancer Center at Milford, Milford, MA, USA.<br /><searchLink fieldCode="AU" term="%22Spring+LM%22">Spring LM</searchLink>; Harvard Medical School, Boston, MA, USA.; Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Faggen+M%22">Faggen M</searchLink>; Harvard Medical School, Boston, MA, USA.; Hematology/Oncology, Dana-Farber/Brigham and Women's Cancer Center at South Shore Hospital, South Weymouth, MA, USA.<br /><searchLink fieldCode="AU" term="%22Constantine+M%22">Constantine M</searchLink>; Harvard Medical School, Boston, MA, USA.; Hematology/Oncology, Dana-Farber/Brigham and Women's Cancer Center at Milford, Milford, MA, USA.<br /><searchLink fieldCode="AU" term="%22Metzger+O%22">Metzger O</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Alberti+J%22">Alberti J</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Deane+J%22">Deane J</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Clinical Affairs, TransMedics, Inc, Andover, MA, USA.<br /><searchLink fieldCode="AU" term="%22Rosenberg+SM%22">Rosenberg SM</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Frank+E%22">Frank E</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Tolaney+SM%22">Tolaney SM</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Krop+IE%22">Krop IE</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Yale Cancer Center, New Haven, CT, USA.<br /><searchLink fieldCode="AU" term="%22Tung+NM%22">Tung NM</searchLink>; Harvard Medical School, Boston, MA, USA.; Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Tayob+N%22">Tayob N</searchLink>; Harvard Medical School, Boston, MA, USA.; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22King+TA%22">King TA</searchLink>; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Mittendorf+EA%22">Mittendorf EA</searchLink>; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Winer+EP%22">Winer EP</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Eric.winer@yale.edu.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA. Eric.winer@yale.edu.; Harvard Medical School, Boston, MA, USA. Eric.winer@yale.edu.; Yale Cancer Center, New Haven, CT, USA. Eric.winer@yale.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101674891%22">NPJ breast cancer</searchLink> [NPJ Breast Cancer] 2022 May 10; Vol. 8 (1), pp. 63. <i>Date of Electronic Publication: </i>2022 May 10.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Breast+Cancer+Research+Foundation%22">Breast Cancer Research Foundation </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101674891 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>2374-4677 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223744677%22">23744677 </searchLink><i>NLM ISO Abbreviation: </i>NPJ Breast Cancer <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35538105
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41523-022-00429-7
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 63
    Titles:
      – TitleFull: A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Waks AG
      – PersonEntity:
          Name:
            NameFull: Desai NV
      – PersonEntity:
          Name:
            NameFull: Li T
      – PersonEntity:
          Name:
            NameFull: Poorvu PD
      – PersonEntity:
          Name:
            NameFull: Partridge AH
      – PersonEntity:
          Name:
            NameFull: Sinclair N
      – PersonEntity:
          Name:
            NameFull: Spring LM
      – PersonEntity:
          Name:
            NameFull: Faggen M
      – PersonEntity:
          Name:
            NameFull: Constantine M
      – PersonEntity:
          Name:
            NameFull: Metzger O
      – PersonEntity:
          Name:
            NameFull: Alberti J
      – PersonEntity:
          Name:
            NameFull: Deane J
      – PersonEntity:
          Name:
            NameFull: Rosenberg SM
      – PersonEntity:
          Name:
            NameFull: Frank E
      – PersonEntity:
          Name:
            NameFull: Tolaney SM
      – PersonEntity:
          Name:
            NameFull: Krop IE
      – PersonEntity:
          Name:
            NameFull: Tung NM
      – PersonEntity:
          Name:
            NameFull: Tayob N
      – PersonEntity:
          Name:
            NameFull: King TA
      – PersonEntity:
          Name:
            NameFull: Mittendorf EA
      – PersonEntity:
          Name:
            NameFull: Winer EP
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 10
              M: 05
              Text: 2022 May 10
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 2374-4677
          Numbering:
            – Type: volume
              Value: 8
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: NPJ breast cancer
              Type: main
ResultId 1